Skip to main content

Table 1 Patients’ characteristics and clinical features

From: VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

Patient Tumor location N surgeries pre-bev n bev cycles Best response Toxicity (grade) PFS (mos) OS (mos)
1 R temporal 3 11 CR none 51 71
2 R parietal 1 12 CR none 36 41
3 R temporal 1 1 PD brain hemorrhage 3 4
4 R parietal 2 2 SD hepatic failure 6 8
5 L temporal 1 9 CR none 40 48
6 multifocal 1 2 PD brain hemorrhage 6 7
7 L occipital 1 NA NA NA NA NA
8 multifocal 1 NA NA NA NA NA
9 L parietal 2 NA NA NA NA NA
10 R parietal 1 NA NA NA NA NA
11 R temporal 1 NA NA NA NA NA
12 L parietal 1 NA NA NA NA NA